What aguettant does

Aguettant (Laboratoire Aguettant) is a French pharmaceutical laboratory founded in 1835 and headquartered in Lyon, France, specializing in the development, manufacture, and distribution of essential injectable medicines for hospitals. The company operates as an independent SAS (share capital €12.7 million) and serves anesthesia, resuscitation, emergency, neurology, nutrition, and perfusion therapeutic areas through multiple pharmaceutical forms including pre-filled syringes (SAFIR brand, 13 medications), polypropylene ampoules (blow-fill-seal technology), glass ampoules, perfusion bags, glass vials, injector pens, and cartridges. Five industrial sites in France handle integrated manufacturing: Lyon-Gerland (headquarters and R&D), Champagne-Ardèche (pre-filled syringes and blow-fill-seal ampoules), Saint-Fons (distribution), Grenoble (R&D and Promise Proteomics), and Lille-Mouvaux (sterile infusion bags, acquired April 2024). The company employs approximately 1,700 people globally, with the majority in France, and reached 60 million ampoule/year production capacity following a €40 million manufacturing extension completed in April 2024.

The company generates revenue primarily via B2B pharmaceutical sales to hospitals and healthcare institutions through ten wholly-owned commercial entities across Europe, Asia, and Canada, complemented by distribution partnerships in 90+ countries. An enterprise field sales model targets hospital formularies and procurement, supported by an event-driven go-to-market approach (presence at ESA, ESRA, EUSEM, and CPHI congresses) and an educational platform (Aguettant Academy) for healthcare professionals. Beyond injectables, Aguettant has diversified into in vitro diagnostics through two wholly-owned subsidiaries: Aguettant Diagnostics (CBRN medical countermeasures) and Promise Proteomics (mass spectrometry-based quantification and stable isotope-labeled protein products for biotherapy monitoring). Distribution agreements extend into the US, Latin America, Japan, Korea, and India. Regulatory positioning rests on pharmaceutical establishment authorization from ANSM, hundreds of marketing authorizations worldwide, and ISO 14001:2015 environmental certification, with the company explicitly positioned as a French pharmaceutical sovereignty player (France Relance Plan selection 2020).

Name

aguettant

Legal name

Laboratoire Aguettant

Website

https://aguettant.com

Company type

Private

Founded year

1835

Operating status

Operating

Headcount range

11–50 employees

Short description

Aguettant is a French pharmaceutical laboratory founded in 1835 that develops, manufactures, and distributes essential injectable medicines (pre-filled syringes, ampoules, perfusion bags) for hospitals worldwide, employing ~1,700 people across five French industrial sites and ten international commercial subsidiaries.

Ownership category

akta.pro rank

Product category

Hospital Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Unit-Dose & Compliance Packaging (Sachets, Strip Packs, Pill Organizers) (IMALAIAH), Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes) (IMALAEAB), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Hospital injectable pharmaceuticals
• Pre-filled syringes
• Pharmaceutical manufacturing
• In vitro diagnostics
• Infusion solutions

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices16 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of essential injectable medicines to hospitals and healthcare institutions, including pre-filled syringes, ampoules, perfusion solutions, and other hospital pharmaceutical products. Revenue generated through direct sales via subsidiaries and distribution partnerships.
2. In Vitro Diagnostics Products: Sale of diagnostic solutions through Aguettant Diagnostics and Promise Proteomics subsidiaries, including diagnostic kits for biotherapy monitoring.
3. Licensing and Distribution Partnerships: Licensing agreements for SAFIR pre-filled syringes and pipeline products for geographic expansion to US, Latin America, Japan, Korea, and India.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Aguettant develops, manufactures, and distributes essential injectable medicines for hospitals, with its flagship SAFIR range offering 13 ready-to-use pre-filled polypropylene syringes covering anesthesia, resuscitation, emergency medicine, neurology, and nutrition. The company also produces glass ampoules, polypropylene ampoules via blow-fill-seal technology, perfusion bags, and injector pens, and operates in vitro diagnostics subsidiaries (Promise Proteomics and Aguettant Diagnostics) for biotherapy monitoring and CBRN medical countermeasures.

Product overview

Aguettant is an integrated pharmaceutical laboratory offering essential injectable hospital medicines across multiple therapeutic areas (anesthesia, emergency, analgesia, neurology, nutrition, perfusion). The core portfolio includes SAFIR pre-filled syringes, essential injectable medicines in various forms (ampoules, bottles, perfusion bags, injector pens), and in vitro diagnostics through subsidiaries Aguettant Diagnostics and Promise Proteomics. The company operates 5 industrial sites in France and maintains commercial presence through 10 subsidiaries across Europe, Asia, and Canada.

Differentiator

Problem solved

Functional benefit

Brands

• Aguettant Diagnostics: Integrated company dedicated to the design, development, manufacturing and registration of diagnostic solutions.
• Promise Proteomics
• SAFIR
• Aguettant Mouvaux
• Aguettant Academy

Products and services

• SAFIR Pre-filled Syringes Polypropylene pre-filled syringes delivered sterile and ready-to-use in individual packaging, designed to prevent medication errors, reduce contamination risk, and improve patient safety in hospital settings, particularly in anesthesia, resuscitation, and emergency services. Thirteen injectable medications are available in this format, featuring tamper-evident seals, Luer-compatible connectors, double graduation markings, and ISO 26825 labels.
• Essential Injectable Medicines Essential hospital injectable drugs covering therapeutic areas including anesthesia, emergency medicine, surgery, analgesia, nutrition (micronutrients), neurology (Parkinson's disease, epilepsy, spasticity), and perfusion solutions. Products available in multiple pharmaceutical forms including ampoules, glass bottles, perfusion bags, and injector pens.
• Sterile Infusion Bags Sterile perfusion bags in plastic containers ranging from 50ml to 1 liter, manufactured at the Aguettant Mouvaux site (formerly Carelide), acquired in April 2024.
• Aguettant Diagnostics Integrated subsidiary dedicated to the design, development, manufacturing, and registration of in vitro diagnostic solutions, including medical countermeasures against CBRN (Chemical, Biological, Radiological, and Nuclear) risks.
• Promise Proteomics mAbXmise Kits MedTech subsidiary specializing in mass spectrometry-based quantification methods and bioproduction of stable isotope-labeled (SIL) proteins. Offers mAbXmise kits for healthcare professionals for biological monitoring of biotherapies.

Quantifiable outcome

• 17x higher medication error risk when injectable preparation is performed manually vs using pre-filled syringes
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• DelpharmcoreStrategic or Co-development Partner · 1 January 2023Collaboration between Aguettant and Delpharm to take over the Carelide Laboratory (Mouvaux site in Northern France). Aguettant became sole owner in April 2024, acquiring manufacturing capacity for sterile infusion bags and adding nearly 500 employees.
• TULIPEcoreStrategic or Co-development PartnerTULIPE is the association for emergency and international solidarity of healthcare companies. Aguettant has been a member since 2011. The association provides emergency kits adapted to the needs of populations in distress during acute health crises, natural disasters, or conflicts through donations from member companies.
• Institut du Coeur (Alain Carpentier Foundation)minorStrategic or Co-development PartnerAguettant has actively supported the Alain Carpentier Foundation for 5 years to enable free surgery for underprivileged children in Vietnam.
• Pharmaceutical Distribution PartnerscoreChannel Partner/ Reseller/ DistributorAguettant seeks licensing and distribution partnerships for specialty pharmaceutical products across pan-European geography through commercial infrastructure via subsidiaries, and geographic expansion to US, Latin America, Japan, Korea, and India for SAFIR pre-filled syringes and pipeline products.

Scale indicators11 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Becton Dickinson (BD): Global medical technology leader with a significant Pharmaceutical Systems segment producing pre-filled syringes, injection devices, and drug delivery systems for hospital and biopharma customers. Directly comparable to Aguettant in pre-filled syringe technology and hospital channel.
• B. Braun: German-headquartered global medical and pharmaceutical company with a substantial hospital injectable medicines portfolio (anesthesia, infusion, IV solutions). Directly comparable in therapeutic focus, geographic mix, and B2B hospital sales model.
• Fresenius Kabi: Global leader in injectable pharmaceuticals, infusion therapy, and clinical nutrition for hospital customers. Closely comparable to Aguettant across anesthesia, infusion solutions, nutrition, and pre-filled formats.
• Vetter Pharma: German CDMO specializing in sterile injectable fill-finish including pre-filled syringes and complex delivery formats. Comparable in pre-filled syringe manufacturing technology and European hospital/biopharma customer base.
• Hikma Pharmaceuticals: Specialty pharmaceutical company with a major injectables business supplying hospitals across the US, Europe, and MENA. Directly comparable in essential injectable hospital medicines, including anesthesia and critical care.
• Stevanato Group: Italian-headquartered supplier of drug containment, drug delivery (including pre-filled syringes), and diagnostic solutions. Comparable as a vertically integrated manufacturer of glass and plastic pre-fillable systems serving injectables customers.
• Nipro Corporation: Japanese medical and pharmaceutical manufacturer with a strong injectables portfolio (pre-filled syringes, ampoules, vials) and global hospital distribution. Comparable across product formats and international scope.

Broad incumbents

• West Pharmaceutical Services: Global leader in primary packaging and delivery systems for injectable drugs, including pre-filled syringe components and elastomeric closures. Comparable as a supplier to the same injectable ecosystem, though primarily a components provider rather than a finished-drug manufacturer.
• SCHOTT Pharma: Global supplier of pharmaceutical primary packaging including ampoules, vials, syringes, and cartridges. Comparable in glass ampoules and pre-fillable syringe systems used by injectable drug manufacturers including Aguettant.

Emerging players

• Gerresheimer: European-headquartered specialist in pharmaceutical glass and plastic packaging including vials, ampoules, and pre-fillable syringes. Comparable as a partner/competitor in glass ampoules and pre-filled syringe formats that Aguettant manufactures.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aguettant-ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about aguettant